Gillian McGovern, Associate Editor

PLT012 demonstrates its potential against multiple tumors with unmet medical needs.

Two studies found a 2-bag regimen of N-acetylcysteine (NAC) resulted in fewer and shorter delays in treatment as well as decreases in cutaneous non-allergic anaphylactoid reactions.

This builds off prior data that showed safety and efficacy of CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL).

If approved, the treatment will be the first and only once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist available for acromegaly.

In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.

The US Department of Agriculture’s (USDA) guidance will help expedite H5N1 bird flu surveillance within the nation’s milk supply and dairy herds.

The authors found high exposure to butylparaben and low exposure to 4-nonylphenol during pregnancy were risk factors for asthma development in children at 4 years of age.

Children born moderate to late preterm also showed more behavior difficulties compared with those born early term or later.

The authors suggest that targeted interventions to mitigate financial toxicity should be implemented to better support patients.

The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.

Sacituzumab tirumotecan (sac-TMT; Kelun Pharmaceutical, Merck) is currently being studied to treat non-small cell lung cancer (NSCLC) in the TroFuse-004 and TroFuse-009 trials.

These risks were observed to become higher as gestational age decreased.

The authors recommend that longer assessments with lengthier interventions should be performed to assess potential benefits.

If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.

When different skin tones are considered in imaging systems, women will receive more equitable screening and care.

Asthma onset earlier in childhood may be linked to more severe difficulties that could extend to executive function abilities.

Potential solutions can include international funding, improved primary health care measures, and cost-effective screening methods.

These findings are significant in understanding interactions between glucagon-like peptide-1 medications and thyroid dysfunction because prior research has shown conflicting results.

Because these cells are present throughout the body, there may also be implications for other cancer types.

Postpartum depression (PPD) rates also had notable increases in those with class I and class II/III obesity.

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

Community health care workers help support both primary care and school settings by assisting with medication administration and communications with staff.

The guidelines were expanded to include the growing use of genetic testing within cancer prevention, screening, and treatment.

If approved, RAG-21 can offer improved outcomes in patients with amyotrophic lateral sclerosis (ALS), particularly those with aggressive subtypes.

Women aged 40 to 44 years at the time of natural menopause showed about a 30% decreased risk for asthma incidence.

The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.

If patterns and trends were to continue, the authors predict that nationwide overweight and obesity prevalence in adults will surpass 80% by 2050.

Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.